Adults aged 60–74 years who do not have a risk factor for severe RSV disease can consider a single dose of RSV vaccine. People in this age group have a lower risk of severe RSV disease than people aged ≥75 years, so the benefit may be less than in people aged ≥75 years.
RSV vaccine may be given at any time of the year but, where possible, should be offered before the start of the RSV season. Adults recommended to receive an RSV vaccine, who have previously had an RSV infection, can receive it once they are recovered.
Either Abrysvo or Arexvy may be used, with no brand preference.
Protection lasts for at least 2 years, and the need for further doses has not been established.
